CytRx (CYTR) Tops Q1 EPS by 52c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
CytRx Announces Publication of Glioblastoma Clinical Case Study in Journal of Nuclear Medicine & Radiation Therapy
April 29, 2015 9:00 AM EDTLOS ANGELES, April 29, 2015 /PRNewswire/ --Â CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that a case study, titled "Albumin-Linked Doxorubicin (Aldoxorubicin) as Treatment for Relapsed Glioblastoma: A Case Report," has been published online in the Journal of Nuclear Medicine & Radiation Therapy (Volume 6, Issue 2).
The paper reviews the case of a 54 year old male patient with recurrent left parietal lobe glioblastoma multiforme (GBM), a deadly form of brain cancer. The patient had completed treatment with radiation and temozolomide more than two years... More
